Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 7

1.
Fig. 3

Fig. 3. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 3 who declined from normal cognition to DAT and received a postmortem diagnosis of definite AD. a, b See legend to Fig. 1

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
2.
Fig. 6

Fig. 6. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 6 who progressed from mild DAT to probable vascular dementia in life and received a post-mortem diagnosis of definite AD. a, b See legend to Fig. 1

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
3.
fig. 2

fig. 2. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 2 who declined from normal cognition to MCI and received a postmortem diagnosis of Parkinson's disease with additional AD-related pathological lesions. a, b See legend to Fig. 1

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
4.
Fig. 5

Fig. 5. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 5 who progressed from mild to severe DAT in life, and received a postmortem diagnosis of definite AD. a, b See legend to Fig. 1

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
5.
Fig. 7

Fig. 7. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 7 who progressed from mild to moderate DAT in life and received a post-mortem diagnosis of definite AD. a, b See legend to Fig. 1

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
6.
Fig. 4

Fig. 4. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 4 who declined from normal cognition to DAT and received a postmortem diagnosis of definite AD. a, b See legend to Fig. 1. c Original FDG-PET scans are displayed as transaxial slices 10 mm apart from the bottom (left) to the top (right) of the brain. CMRglc values are displayed on a color-coded scale ranging from 0 to 50 μmol/ 100 g per minute

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.
7.
Fig. 1

Fig. 1. From: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Progression of CMRglc abnormalities in patient 1 who declined from normal cognition to MCI and received a postmortem diagnosis of probable AD. a 3D-SSP maps and corresponding Z scores reflecting CMRglc reductions in the patient as compared with the normative database are displayed using a color-coded scale ranging from 0 (black)to 6(red) on the right and left lateral, superior, inferior, anterior, posterior, right and left medial views of a standardized brain template image. b Regional CMRglc values at each timepoint are compared to reference control values (white; error bars are standard errors) [25]. *p≤ 0.05 vs controls (IPL inferior parietal lobe, HIP hippocampus, LTL lateral temporal lobe, PCC posterior cingulate cortex, FCx frontal cortex; L left, R right hemisphere)

Lisa Mosconi, et al. Eur J Nucl Med Mol Imaging. ;36(5):811-822.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk